Head-to-head evidence
Giredestrant vs tamoxifen
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Giredestrant
Developed by Roche
NCT04436744 · Phase 2 · completed
This was a randomized but unblinded trial of 221 patients using a tumor biomarker (Ki67), rather than a hard clinical outcome such as tumor response or survival, as its primary measure; the giredestrant combination produced a statistically significant reduction in this biomarker compared with the anastrozole combination.
Next expected readout: July 2027 · NCT03332797 (registry estimate)
tamoxifen
Marketed by Mayne Pharma
NCT00066690 · Phase 3 · completed
The trial was large and randomized, with tamoxifen as an active comparator, but it was open-label rather than blinded. Its hard primary endpoint, five-year disease-free survival, produced mixed results: exemestane plus ovarian suppression was superior to tamoxifen alone, whereas tamoxifen plus ovarian suppression was not statistically significant compared with tamoxifen alone.
Next expected readout: October 2026 · NCT03707340 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Giredestrant's landscape · tamoxifen's landscape